HIV Vaccine Disappointment: Trial Data Show Lack of Sufficient Protection

This week, the National Institute of Allergy and Infectious Diseases released a disappointing update from a Phase IIb proof-of-concept study for an investigational HIV vaccine made by Johnson & Johnson. The data from the “Imbokodo” clinical trial, conducted in sub-Saharan Africa, suggest that the HIV vaccine—with an efficacy of 25.2%—showed a lack of sufficient protection in women. Notably, the vaccine posed no safety concerns.